Showing 1931-1940 of 3314 results for "".
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- Ocuphire Expands Medical Advisory Board with Seven New KOLs; Expands Leadership Teamhttps://modernod.com/news/ocuphire-expands-medical-advisory-board-with-seven-new-kols-expands-leadership-team/2481132/Ocuphire Pharma announced that it has appointed seven new key opinion leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, MS, has been promoted to Vice President, Business Development and Market St
- Johnson & Johnson Vision Expands Access to Myopia Management for More Patients With Abiliti Overnight Lenseshttps://modernod.com/news/johnson-johnson-vision-expands-access-to-myopia-management-for-more-patients-with-abiliti-overnight-lenses/2481127/Johnson & Johnson Vision announced FDA approval of an expanded range of ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management, now up to 6.00 diopters (previously 4.00 diopters). Johnson & Johnson Vision also announced greater availability of the lenses nationwi
- Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001https://modernod.com/news/frontera-therapeutics-receives-additional-ind-clearance-for-its-lead-program-ft-001/2481106/Frontera Therapeutics announced that its lead program, FT-001, a gene therapy product candidate targeting inherited retinal degenerations (IRDs) with a RPE65 mutation, successfully obtained an IND from the Center for Drug Evaluation (CDE), NMPA, in China. The FDA also cleared an IND for
- California Legislature Passes Optometric Surgery Billhttps://modernod.com/news/california-legislature-passes-optometric-surgery-bill/2481077/The California Legislature recently passed AC 2236, an optometric surgery bill that, if signed into law, would expand optometrists’ scope of practice in California to include some scalpel and
- Lensar Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EUhttps://modernod.com/news/lensar-announces-application-for-certification-of-the-ally-adaptive-cataract-treatment-system-in-the-eu/2481069/Lensar announced the application for certification of the ALLY Adaptive Cataract Treatment System in the European Union. “Following the FDA clearance of ALLY in June 2022 and recent US commercial launch, this is another important step in our effort to bring ALLY to
- First SBL-3 ClearView Multifocal Intraocular Lens Implanted in UShttps://modernod.com/news/first-sbl-3-clearview-multifocal-intraocular-lens-implanted-in-us/2481031/Lenstec announce that the first US commercial implantations of their newly FDA approved SBL-3 ClearView Multifocal IOL (MIOL) were performed by Jeff Whitsett, MD, of Whitsett Vision, Houston, Texas. The SBL-3 Clearview Multifocal is a next-generation presbyopia-
- First Patients Treated with Lensar's ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/first-patients-treated-with-lensars-ally-adaptive-cataract-treatment-system/2481029/Lensar announced the first commercial cases performed with the ALLY Adaptive Cataract Treatment System by Robert Weinstock, MD, at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted cataract surgery cases following the recent installation of his ALLY Syste
- Lenstec Receives FDA Approval for the SBL-3 Multifocal IOLhttps://modernod.com/news/lenstec-receives-fda-approval-for-sbl-3-multifocal-iol/2481002/Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL (Segmented Bifocal Lens) is a next-generation asymmetric multifocal refractive IOL that provides patients with near, intermediate and distance vision. Its patented design allows for improved contrast sensit
- LKC Appoints New Members of Sales and Marketing Leadershiphttps://modernod.com/news/lkc-appoints-new-members-of-sales-and-marketing-leadership/2480999/LKC Technologies, a provider of electroretinography devices, announced the hiring of two industry professionals to lead their strategic efforts to expand its foothold in the US optometric market. Gary VanMatre was appointed Vice President, US Sales, and will lead a geographica